Laserscope KTP
This article was originally published in The Gray Sheet
Executive Summary
Laser system for treatment of benign prostatic hyperplasia (BPH) gains FDA market go-ahead, announced May 10. Commercial shipments are anticipated to begin later this year. Three-year follow-up data showing effectiveness comparable to TURP (trans-urethral resection of the prostate) will be presented at the American Urological Association meeting in Anaheim June 2-7